O. Lapuente-Santana

The paper evaluates predictive models for immune checkpoint inhibitor outcomes in NSCLC using clinical trial data from two RCTs, finding that models combining PD-L1, TMB, and immune signatures outperform single biomarkers.

This study develops EaSIeR, a method using RNA-seq data and prior knowledge to predict immune response to PD-1 inhibitors by analyzing tumor microenvironment signatures.